<code id='734859E01F'></code><style id='734859E01F'></style>
    • <acronym id='734859E01F'></acronym>
      <center id='734859E01F'><center id='734859E01F'><tfoot id='734859E01F'></tfoot></center><abbr id='734859E01F'><dir id='734859E01F'><tfoot id='734859E01F'></tfoot><noframes id='734859E01F'>

    • <optgroup id='734859E01F'><strike id='734859E01F'><sup id='734859E01F'></sup></strike><code id='734859E01F'></code></optgroup>
        1. <b id='734859E01F'><label id='734859E01F'><select id='734859E01F'><dt id='734859E01F'><span id='734859E01F'></span></dt></select></label></b><u id='734859E01F'></u>
          <i id='734859E01F'><strike id='734859E01F'><tt id='734859E01F'><pre id='734859E01F'></pre></tt></strike></i>

          fashion

          fashion

          author:Wikipedia    Page View:85
          Blue numbers and letter falling down a tunnel. -- health tech coverage from STAT
          Adobe

          A growing number of AI tools are being used to predict everything from sepsis to strokes, with the hope of accelerating the delivery of life-saving care. But over time, new research suggests, these predictive models can become a victim of their own success — sending their performance into a nosedive and generating inaccurate, potentially harmful results.

          “There is no accounting for this when your models are being tested,” said Akhil Vaid, an instructor of data-driven and digital medicine at the Icahn School of Medicine at Mount Sinai and author of the new research, published Monday in the Annals of Internal Medicine. “You can’t run validation studies, do external validation, run clinical trials — because all they’ll tell you is that the model works. And when it starts to work, that is when the problems will arise.”

          advertisement

          Vaid and his Mount Sinai colleagues simulated the deployment of two models that predicted a patient’s risk of dying and acute kidney injury within five days of entering the ICU. Their simulations assumed that the models did what they were supposed to — lower deaths and kidney injury by identifying patients for earlier intervention.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Fight over Supreme Court dialysis ruling puts kidney patients at risk
          Fight over Supreme Court dialysis ruling puts kidney patients at risk

          AdobeAssoonassheheardtheSupremeCourtdecision,LaVarneBurtonbegantoworry.AsCEOofthenonprofitAmericanKi

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Pioneering cancer drug will cost $475,000. Analysts call it a bargain

          VictorSeguraIbarraandRitaSerda,Ph.D.,NCI,NIHTheFoodandDrugAdministrationonWednesdayapprovedafuturist